Astellas Pharma

...Bothell, WA-based developer of cancer drugs, said today it will get a $12 million upfront fee from Agensys, an affiliate of Japan-based Astellas Pharma, under a renegotiated partnership to develop targeted antibody treatments loaded with...

In this article: Seattle, Cancer, Toxin, All rights reserved, WordPress, Twitter, and Nasdaq

Earlier this month, Ironwood agreed to license the rights to commercialize Linaclotide in several Asian countries to a Japanese company, Astellas Pharma Inc., in exchange for $75 million. Material from Globe wire services was used in this...

In this article: Irritable bowel syndrome, Cambridge, Astellas Pharma Inc., and Massachusetts

TOKYO & SANTA CLARA, Calif. - Astellas Pharma Inc. and XenoPort, Inc. (NASDAQ:XNPT) today announced that a new drug application (NDA) has been filed with the Pharmaceuticals and Medical Device Agency (PMDA) in Japan for ASP8825 (gabapentin...

In this article: Astellas, Japan, Gabapentin, Restless legs syndrome, GlaxoSmithKline, Tokyo, Trademark, Calcium, Parkinson's disease, and Migraine

...yen to build a new factory to produce lithium ion batteries for electric vehicles, the Nikkei business daily reported on Tuesday. Astellas Pharma Inc <4503. T> The U.S. Food and Drug Administration has approved NeurogesX Inc's...

In this article: U.S., Ben Bernanke, Mizuho Securities, Astellas Pharma Inc, GS Yuasa Corp, S&P 500, and The Fed

...up to three months, the company said in a statement. In June, NeurogesX Inc <NGSX.O> announced a distribution agreement with Japan's Astellas Pharma Inc <4503. T> to sell Qutenza, in the European Economic Area, the Middle East and Africa.

In this article: Astellas Pharma Inc, U.S. Food and Drug Administration, Africa, Middle East, and Japan

...pre-commercial milestone payments as well as escalating royalties on sales in the territories where Astellas markets the company's drug, linaclotide. Astellas will get exclusive rights to develop and market the product in Japan, Indonesia, the...

In this article: Asia, Laboratorios Almirall, Irritable bowel syndrome, Forest Laboratories, Japan, Twitter, NYSE, and San Diego

...rights to develop and sell U.S. firm Ironwood Pharmaceuticals' drug for irritable bowel syndrome in Japan and other parts of Asia. Astellas will pay $75 million upfront to develop linaclotide, now in Phase III trials in the United States...

In this article: Japan, Irritable bowel syndrome, United States, Taiwan, Asia, Thailand, Indonesia, and South Korea

...capabilities for delivering linaclotide to patients in its territory and we look forward to collaborating with them." About Astellas Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the...

In this article: Astellas, Japan, Irritable bowel syndrome, Tacrolimus, Tokyo, Massachusetts, and United States

...profit growth as cost cuts offset a negative foreign exchange impact and falling drug sales. [ID:nN208741] Astellas also said it would spend up to 30 billion yen ($331 million) to buy back as much as 1.7 percent of its outstanding shares...

In this article: Prograf, Sandoz, United States, Cancer, Takeda Pharmaceutical, Nikkei 225, Pfizer, and Japan

...said on Thursday its recurring profit fell 13 percent in April-September, hit by the stronger yen and competition from a generic drug. Astellas posted a recurring profit of 128.3 billion yen ($1.42 billion) in the half year, down from...

In this article: Astellas, Prograf, Sandoz, Takeda Pharmaceutical, Novartis AG, Pfizer, Japan, and United States